Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is part of a Comprehensive Cancer Center designated by the National Cancer Institute. It is a major affiliate of Harvard Medical School and is located in the Longwood Medical Area in Boston, Massachusetts. Dana-Farber employs more than 3,680 people and has annual revenues of about $800 million. There are more than 299,202 adult and pediatric patient visits a year, and it is involved in more than 700 clinical trials. It is internationally known for its research and clinical excellence, having been ranked the sixth best cancer hospital in the United States by U.S. News & World Report. Dana-Farber is a member of the Multiple Myeloma Research Consortium. In addition to being a principal teaching affiliate of Harvard Medical School, Dana-Farber is also a federally designated Center for AIDS Research, and a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), a federally designated comprehensive cancer center.
New protein-targeting drug shows promise in early trial for patients with high-risk CLL
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL), according to a study led in part by ...
Cancer
May 17, 2013 |
not rated yet |
0
|
Scientists find mutation driving pediatric brain tumors
A type of low-grade but sometimes lethal brain tumor in children has been found in many cases to contain an unusual mutation that may help to classify, diagnose and guide the treatment of the tumors, report scientists at ...
Genetics
Apr 30, 2013 |
5 / 5 (1) |
0
|
Toxicity differences inform decision on conditioning for neuroblastoma transplants
MIAMI—The stem cell transplant regimen that was commonly used in the United States to treat advanced neuroblastoma in children appears to be more toxic than the equally effective regimen employed in Europe and Egypt, according ...
Cancer
Apr 24, 2013 |
not rated yet |
0
Delays in diagnosis worsen outlook for minority, uninsured pediatric retinoblastoma patients
When the eye cancer retinoblastoma is diagnosed in racial and ethnic minority children whose families don't have private health insurance, it often takes a more invasive, potentially life-threatening course than in other ...
Cancer
Apr 24, 2013 |
not rated yet |
1
Majority of children readmitted to hospital following stem cell transplant
Nearly two-thirds of children receiving stem cell transplants returned to the hospital within six months for treatment of unexplained fevers, infections or other problems, according to a study performed at Dana-Farber/Children's ...
Cancer
Apr 24, 2013 |
not rated yet |
0
Genetic biomarker may help identify neuroblastomas vulnerable to novel class of drugs
An irregularity within many neuroblastoma cells may indicate whether a neuroblastoma tumor, a difficult-to-treat, early childhood cancer, is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors, ...
Cancer
Apr 09, 2013 |
not rated yet |
0
Some patients with incurable tumors and BRCA mutations respond to new two-drug combination
A novel combination of two drugs has shown anti-cancer activity in patients who had incurable solid tumors and carried a germline mutation in their BRCA genes, Dana-Farber Cancer Institute researchers are reporting at the ...
Cancer
Apr 07, 2013 |
5 / 5 (1) |
0
Blood tests can provide fuller picture of mutations in cancer than traditional biopsies do
A new blood test revealed more of the gene mutations that sustain certain digestive-tract tumors than did a DNA analysis of a traditional tumor biopsy, Dana-Farber Cancer Institute investigators will report at a special symposium ...
Cancer
Apr 07, 2013 |
not rated yet |
0
Targeted toxin active in platinum-resistant ovarian cancers
A new antibody-guided drug has shown promising activity in a phase I trial involving ovarian cancer patients with platinum drug-resistant disease, researchers from Dana-Farber Cancer Institute will report today at the annual ...
Cancer
Apr 06, 2013 |
not rated yet |
0
Scientists find potential loophole in pancreatic cancer defenses
Dana-Farber Cancer Institute scientists and colleagues have discovered that pancreatic cancer cells' growth and spread are fueled by an unusual metabolic pathway that someday might be blocked with targeted drugs to control ...
Cancer
Mar 27, 2013 |
5 / 5 (4) |
0
|
Study finds molecular 'signature' for rapidly increasing form of esophageal cancer
During the past 30 years, the number of patients with cancers that originate near the junction of the esophagus and stomach has increased approximately 600 percent in the United States. The first extensive probe of the DNA ...
Cancer
Mar 24, 2013 |
not rated yet |
0
|
Study tracks leukemia's genetic evolution, may help predict disease course, tailor care
Tumors are not factories for the mass production of identical cancer cells, but are, in reality, patchworks of cells with different patterns of gene mutations. In a new study, researchers at Dana-Farber Cancer Institute and ...
Cancer
Feb 14, 2013 |
5 / 5 (1) |
0
New strategy prevents rheumatoid arthritis in mice
Dana-Farber Cancer Institute scientists have demonstrated a new strategy for treating autoimmune disease that successfully blocked the development of rheumatoid arthritis in a mouse model. They say it holds promise for improved ...
Arthritis & Rheumatism
Feb 08, 2013 |
5 / 5 (3) |
0
|
New mutations driving malignant melanoma discovered
Two new mutations that collectively occur in 71 percent of malignant melanoma tumors have been discovered in what scientists call the "dark matter" of the cancer genome, where cancer-related mutations haven't ...
Cancer
Jan 24, 2013 |
not rated yet |
0
|
Genomic sequencing identifies mutant 'drivers' of common brain tumor
Large-scale genomic sequencing has revealed two DNA mutations that appear to drive about 15 percent of brain tumors known as meningiomas, a finding that could lead to the first effective drug treatments for the tumors, report ...
Genetics
Jan 22, 2013 |
not rated yet |
0
|
